What is Gyre Therapeutics Inc's earnings per share (EPS)?

Gyre Therapeutics Inc (GYRE) reported diluted earnings per share of $0.02 for fiscal year 2025. This represents a -60.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Gyre Therapeutics Inc Financials

GYRE

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Gyre Therapeutics Inc (GYRE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 57/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Gyre Therapeutics Inc has an operating margin of 9.8%, meaning the company retains $10 of operating profit per $100 of revenue. This results in a moderate score of 44/100, indicating healthy but not exceptional operating efficiency. This is down from 15.3% the prior year.

Growth

Gyre Therapeutics Inc's revenue grew 10.2% year-over-year to $116.6M, a solid pace of expansion. This earns a growth score of 50/100.

Leverage

Gyre Therapeutics Inc carries a low D/E ratio of 0.57, meaning only $0.57 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 90/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 5.60, Gyre Therapeutics Inc holds $5.60 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While Gyre Therapeutics Inc generated $1.0M in operating cash flow, capex of $1.2M consumed most of it, leaving -$180K in free cash flow. This results in a low score of 25/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Gyre Therapeutics Inc's ROE of 9.3% shows moderate profitability relative to equity, earning a score of 32/100. This is down from 28.3% the prior year.

Altman Z-Score Safe

7.45

Gyre Therapeutics Inc scores 7.45, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($650.2M) relative to total liabilities ($60.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Weak

3/9

Gyre Therapeutics Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.10x

For every $1 of reported earnings, Gyre Therapeutics Inc generates $0.10 in operating cash flow ($1.0M OCF vs $9.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage Safe

6.6x

Gyre Therapeutics Inc earns $6.6 in operating income for every $1 of interest expense ($11.5M vs $1.7M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$116.6M

YoY+10.2%

5Y CAGR+41.0%

Gyre Therapeutics Inc generated $116.6M in revenue in fiscal year 2025. This represents an increase of 10.2% from the prior year.

EBITDA

$14.0M

YoY-21.1%

Gyre Therapeutics Inc's EBITDA was $14.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 21.1% from the prior year.

Net Income

$9.9M

YoY-44.8%

Gyre Therapeutics Inc reported $9.9M in net income in fiscal year 2025. This represents a decrease of 44.8% from the prior year.

EPS (Diluted)

$0.02

YoY-60.0%

Gyre Therapeutics Inc earned $0.02 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 60.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$180K

YoY+97.0%

Gyre Therapeutics Inc generated -$180K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 97.0% from the prior year.

Cash & Debt

$37.1M

YoY+213.8%

5Y CAGR+4.1%

10Y CAGR+2.5%

Gyre Therapeutics Inc held $37.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

91M

YoY+5.8%

5Y CAGR+32.8%

Gyre Therapeutics Inc had 91M shares outstanding in fiscal year 2025. This represents an increase of 5.8% from the prior year.

Margins & Returns

Gross Margin

95.3%

YoY-1.0pp

Gyre Therapeutics Inc's gross margin was 95.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.0 percentage points from the prior year.

Operating Margin

9.8%

YoY-5.4pp

5Y CAGR+283.7pp

Gyre Therapeutics Inc's operating margin was 9.8% in fiscal year 2025, reflecting core business profitability. This is down 5.4 percentage points from the prior year.

Net Margin

8.5%

YoY-8.4pp

5Y CAGR+276.9pp

Gyre Therapeutics Inc's net profit margin was 8.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 8.4 percentage points from the prior year.

Return on Equity

9.3%

YoY-18.9pp

5Y CAGR+83.3pp

10Y CAGR+56.3pp

Gyre Therapeutics Inc's ROE was 9.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 18.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$13.7M

YoY+13.9%

5Y CAGR-23.7%

10Y CAGR+8.7%

Gyre Therapeutics Inc invested $13.7M in research and development in fiscal year 2025. This represents an increase of 13.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$1.2M

YoY-48.6%

10Y CAGR+15.9%

Gyre Therapeutics Inc invested $1.2M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 48.6% from the prior year.

GYRE Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$116.6M+10.2%	$105.8M-6.8%	$113.5M+10.9%	$102.3M+1294.0%	$7.3M-65.0%	$20.9M
Cost of Revenue	$5.4M+39.4%	$3.9M-16.2%	$4.6M-3.3%	$4.8M	N/A	N/A
Gross Profit	$111.2M+9.1%	$101.9M-6.4%	$108.8M+11.6%	$97.5M	N/A	N/A
R&D Expenses	$13.7M+13.9%	$12.0M-12.7%	$13.8M-17.4%	$16.7M-75.8%	$68.9M+30.0%	$53.0M
SG&A Expenses	$20.8M+29.1%	$16.1M+9.9%	$14.7M-15.6%	$17.4M-8.4%	$19.0M+17.2%	$16.2M
Operating Income	$11.5M-28.9%	$16.2M+124.0%	-$67.2M-830.5%	$9.2M+110.5%	-$87.9M-53.2%	-$57.4M
Interest Expense	$1.7M+12.9%	$1.5M+48.2%	$1.0M+43.8%	$726K	N/A	N/A
Income Tax	$4.6M-14.4%	$5.3M-37.5%	$8.5M+67.0%	$5.1M	N/A	N/A
Net Income	$9.9M-44.8%	$17.9M+120.9%	-$85.5M-2081.5%	$4.3M+104.9%	-$87.9M-56.4%	-$56.2M
EPS (Diluted)	$0.02-60.0%	$0.05+103.5%	$-1.41-4800.0%	$0.03+101.0%	$-2.87	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$37.2M+21.7%	$30.6M+14.2%	$26.8M+21.4%	$22.1M-20.9%	$27.9M+9.4%	$25.5M+1.0%	$25.2M-7.2%	$27.2M
Cost of Revenue	$1.7M+7.1%	$1.6M+41.4%	$1.2M+28.7%	$894K-24.0%	$1.2M+22.9%	$958K+24.4%	$770K-21.3%	$979K
Gross Profit	$35.5M+22.5%	$28.9M+12.9%	$25.6M+21.1%	$21.2M-20.7%	$26.7M+8.8%	$24.5M+0.3%	$24.5M-6.6%	$26.2M
R&D Expenses	$4.8M+103.8%	$2.4M-31.0%	$3.4M+10.7%	$3.1M-16.6%	$3.7M+33.8%	$2.8M-17.3%	$3.4M+53.8%	$2.2M
SG&A Expenses	$6.7M+55.2%	$4.3M-10.6%	$4.8M-2.5%	$5.0M-9.3%	$5.5M+42.9%	$3.8M+11.7%	$3.4M+0.8%	$3.4M
Operating Income	$118K-98.3%	$6.9M+219.0%	$2.2M-4.5%	$2.3M+241.8%	$665K-84.3%	$4.2M+32.5%	$3.2M-60.4%	$8.1M
Interest Expense	N/A	N/A	N/A	N/A	$346K-33.8%	$523K+49.4%	$350K+6.7%	$328K
Income Tax	$1.3M-23.2%	$1.7M+155.7%	$662K-26.5%	$901K+343.8%	$203K-81.1%	$1.1M-28.3%	$1.5M-41.2%	$2.5M
Net Income	-$1.4M-123.0%	$5.9M+276.6%	$1.6M-57.8%	$3.7M+556.2%	$569K-80.1%	$2.9M-37.1%	$4.5M-54.3%	$9.9M
EPS (Diluted)	N/A	$0.03	$0.00	$0.00	N/A	$0.010.0%	$0.01-66.7%	$0.03

GYRE Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$166.1M+32.5%	$125.4M+7.6%	$116.5M+37.5%	$84.8M+52.3%	$55.7M-41.3%	$94.8M
Current Assets	$102.4M+58.0%	$64.8M+13.2%	$57.2M+15.2%	$49.7M-3.5%	$51.5M-42.5%	$89.5M
Cash & Equivalents	$37.1M+213.8%	$11.8M-64.7%	$33.5M+33.1%	$25.2M-43.2%	$44.3M+46.1%	$30.4M
Inventory	$2.9M-54.3%	$6.3M+48.0%	$4.3M-30.1%	$6.1M	N/A	N/A
Accounts Receivable	$31.1M+58.7%	$19.6M+29.2%	$15.2M	N/A	$1.8M-45.1%	$3.3M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$60.1M-3.2%	$62.1M-53.1%	$132.4M+213.4%	$42.2M+189.8%	$14.6M-22.4%	$18.8M
Current Liabilities	$18.3M-6.3%	$19.5M-2.6%	$20.0M+63.8%	$12.2M-13.6%	$14.2M-20.4%	$17.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$106.0M+67.5%	$63.3M+500.0%	-$15.8M-137.2%	$42.5M+3.5%	$41.1M-46.0%	$76.1M
Retained Earnings	-$68.4M+6.8%	-$73.5M+14.1%	-$85.5M-1256.7%	$7.4M+101.8%	-$402.7M-27.9%	-$314.8M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$166.1M+4.2%	$159.4M+4.4%	$152.6M+17.6%	$129.8M+3.5%	$125.4M+0.1%	$125.2M+3.6%	$120.9M-0.9%	$122.0M
Current Assets	$102.4M+3.8%	$98.6M+8.0%	$91.3M+33.4%	$68.4M+5.7%	$64.8M+18.2%	$54.8M+2.4%	$53.5M-14.7%	$62.7M
Cash & Equivalents	$37.1M-8.2%	$40.4M+10.7%	$36.5M+142.5%	$15.0M+27.4%	$11.8M-25.5%	$15.9M-1.4%	$16.1M-46.0%	$29.8M
Inventory	$2.9M-12.9%	$3.3M-62.5%	$8.9M+12.5%	$7.9M+24.3%	$6.3M-0.7%	$6.4M+13.2%	$5.6M+14.1%	$4.9M
Accounts Receivable	$31.1M+20.1%	$25.9M+5.1%	$24.6M+22.2%	$20.1M+2.9%	$19.6M	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$60.1M+4.6%	$57.5M-5.2%	$60.6M-1.7%	$61.7M-0.7%	$62.1M0.0%	$62.1M+2.4%	$60.6M-7.3%	$65.4M
Current Liabilities	$18.3M+14.9%	$15.9M-6.0%	$16.9M-10.9%	$19.0M-2.7%	$19.5M+32.6%	$14.7M-5.5%	$15.6M-20.1%	$19.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$106.0M+4.0%	$101.9M+10.8%	$92.0M+35.1%	$68.1M+7.6%	$63.3M+0.2%	$63.2M+4.7%	$60.4M+6.6%	$56.6M
Retained Earnings	-$68.4M-2.6%	-$66.7M+5.1%	-$70.3M+0.6%	-$70.8M+3.7%	-$73.5M-0.1%	-$73.4M+1.5%	-$74.5M+4.5%	-$78.0M

GYRE Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$1.0M+127.7%	-$3.6M-114.1%	$25.9M+142.5%	$10.7M+112.7%	-$83.8M-52.1%	-$55.0M
Capital Expenditures	$1.2M-48.6%	$2.3M-72.8%	$8.5M+70.9%	$5.0M+494.2%	$839K	N/A
Free Cash Flow	-$180K+97.0%	-$6.0M-134.3%	$17.4M+205.3%	$5.7M+106.7%	-$84.6M	N/A
Investing Cash Flow	-$474K+97.6%	-$19.9M-0.6%	-$19.8M-43.0%	-$13.8M-128.7%	$48.2M+398.7%	$9.7M
Financing Cash Flow	$24.4M+1059.8%	$2.1M-15.9%	$2.5M+105.6%	-$45.0M-190.8%	$49.6M-17.9%	$60.4M
Dividends Paid	N/A	N/A	N/A	$45.0M	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$5.6M-220.3%	$4.7M+123.9%	$2.1M+1718.6%	-$129K+95.3%	-$2.8M-259.8%	$1.7M+131.4%	-$5.5M-290.5%	$2.9M
Capital Expenditures	$144K-78.4%	$668K+160.9%	$256K+109.8%	$122K+287.7%	-$65K-109.4%	$693K-52.4%	$1.5M+530.3%	$231K
Free Cash Flow	-$5.8M-243.9%	$4.0M+118.8%	$1.8M+829.9%	-$251K+91.1%	-$2.8M-373.3%	$1.0M+114.9%	-$6.9M-361.9%	$2.7M
Investing Cash Flow	$1.8M+248.2%	-$1.2M+59.0%	-$3.0M-254.7%	$2.0M+198.2%	-$2.0M+16.0%	-$2.4M+71.1%	-$8.3M-14.6%	-$7.2M
Financing Cash Flow	$318K-12.9%	$365K-98.4%	$22.4M+1563.0%	$1.3M+39.4%	$964K+197.5%	$324K+107.7%	$156K-76.3%	$658K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GYRE Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	95.3%-1.0pp	96.3%+0.4pp	95.9%+0.6pp	95.3%	N/A	N/A
Operating Margin	9.8%-5.4pp	15.3%+74.5pp	-59.3%-68.3pp	9.0%+1206.8pp	-1197.8%-923.9pp	-273.9%
Net Margin	8.5%-8.4pp	16.9%+92.3pp	-75.3%-79.6pp	4.2%+1202.5pp	-1198.3%-929.8pp	-268.5%
Return on Equity	9.3%-18.9pp	28.3%	N/A	10.2%+224.2pp	-214.0%-140.1pp	-73.9%
Return on Assets	5.9%-8.3pp	14.3%+87.6pp	-73.4%-78.4pp	5.1%+163.1pp	-158.0%-98.7pp	-59.3%
Current Ratio	5.60+2.3	3.32+0.5	2.85-1.2	4.06+0.4	3.63-1.4	5.03
Debt-to-Equity	0.57-0.4	0.98+9.3	-8.36-9.4	0.99+0.6	0.35+0.1	0.25
FCF Margin	-0.1%+5.5pp	-5.6%-21.0pp	15.3%+9.8pp	5.6%+1158.4pp	-1152.8%	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	95.3%+0.6pp	94.7%-1.0pp	95.7%-0.3pp	96.0%+0.2pp	95.8%-0.5pp	96.2%-0.7pp	97.0%+0.6pp	96.4%
Operating Margin	0.3%-22.3pp	22.7%+14.5pp	8.1%-2.2pp	10.3%+7.9pp	2.4%-14.2pp	16.6%+4.0pp	12.7%-17.0pp	29.7%
Net Margin	-3.7%-23.1pp	19.4%+13.5pp	5.9%-11.0pp	16.9%+14.9pp	2.0%-9.2pp	11.2%-6.8pp	18.0%-18.6pp	36.6%
Return on Equity	-1.3%-7.1pp	5.8%+4.1pp	1.7%-3.8pp	5.5%+4.6pp	0.9%-3.6pp	4.5%-3.0pp	7.5%-10.0pp	17.5%
Return on Assets	-0.8%-4.5pp	3.7%+2.7pp	1.0%-1.8pp	2.9%+2.4pp	0.4%-1.8pp	2.3%-1.5pp	3.8%-4.4pp	8.1%
Current Ratio	5.60-0.6	6.19+0.8	5.40+1.8	3.60+0.3	3.32-0.4	3.72+0.3	3.44+0.2	3.22
Debt-to-Equity	0.570.0	0.56-0.1	0.66-0.2	0.91-0.1	0.980.0	0.98-0.0	1.00-0.2	1.15
FCF Margin	-15.5%-28.6pp	13.1%+6.3pp	6.8%+8.0pp	-1.1%+9.0pp	-10.1%-14.2pp	4.0%+31.6pp	-27.6%-37.3pp	9.8%

Similar Companies

Gh Research Plc GHRS

$903.8M

Arrivent Biopharma Inc AVBP

$1.1B

Kalvista Pharm KALV

$1.0B

Mind Medicine MNMD

$1.5B

Immatics N.V IMTX

$1.4B

Frequently Asked Questions

What is Gyre Therapeutics Inc's annual revenue?

Gyre Therapeutics Inc (GYRE) reported $116.6M in total revenue for fiscal year 2025. This represents a 10.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Gyre Therapeutics Inc's revenue growing?

Gyre Therapeutics Inc (GYRE) revenue grew by 10.2% year-over-year, from $105.8M to $116.6M in fiscal year 2025.

Is Gyre Therapeutics Inc profitable?

Yes, Gyre Therapeutics Inc (GYRE) reported a net income of $9.9M in fiscal year 2025, with a net profit margin of 8.5%.

What is Gyre Therapeutics Inc's EBITDA?

Gyre Therapeutics Inc (GYRE) had EBITDA of $14.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Gyre Therapeutics Inc's gross margin?

Gyre Therapeutics Inc (GYRE) had a gross margin of 95.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Gyre Therapeutics Inc's operating margin?

Gyre Therapeutics Inc (GYRE) had an operating margin of 9.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Gyre Therapeutics Inc's net profit margin?

Gyre Therapeutics Inc (GYRE) had a net profit margin of 8.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Gyre Therapeutics Inc's return on equity (ROE)?

Gyre Therapeutics Inc (GYRE) has a return on equity of 9.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Gyre Therapeutics Inc's free cash flow?

Gyre Therapeutics Inc (GYRE) generated -$180K in free cash flow during fiscal year 2025. This represents a 97.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Gyre Therapeutics Inc's operating cash flow?

Gyre Therapeutics Inc (GYRE) generated $1.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Gyre Therapeutics Inc's total assets?

Gyre Therapeutics Inc (GYRE) had $166.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Gyre Therapeutics Inc's capital expenditures?

Gyre Therapeutics Inc (GYRE) invested $1.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Gyre Therapeutics Inc spend on research and development?

Gyre Therapeutics Inc (GYRE) invested $13.7M in research and development during fiscal year 2025.

How many shares does Gyre Therapeutics Inc have outstanding?

Gyre Therapeutics Inc (GYRE) had 91M shares outstanding as of fiscal year 2025.

What is Gyre Therapeutics Inc's current ratio?

Gyre Therapeutics Inc (GYRE) had a current ratio of 5.60 as of fiscal year 2025, which is generally considered healthy.

What is Gyre Therapeutics Inc's debt-to-equity ratio?

Gyre Therapeutics Inc (GYRE) had a debt-to-equity ratio of 0.57 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Gyre Therapeutics Inc's return on assets (ROA)?

Gyre Therapeutics Inc (GYRE) had a return on assets of 5.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Gyre Therapeutics Inc's Altman Z-Score?

Gyre Therapeutics Inc (GYRE) has an Altman Z-Score of 7.45, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Gyre Therapeutics Inc's Piotroski F-Score?

Gyre Therapeutics Inc (GYRE) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Gyre Therapeutics Inc's earnings high quality?

Gyre Therapeutics Inc (GYRE) has an earnings quality ratio of 0.10x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Gyre Therapeutics Inc cover its interest payments?

Gyre Therapeutics Inc (GYRE) has an interest coverage ratio of 6.6x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Gyre Therapeutics Inc?

Gyre Therapeutics Inc (GYRE) scores 57 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.